Apollo Hospitals, Aster DM Healthcare, and Sai Life Sciences have delivered impressive returns of up to 27% thus far in financial year 2026-2027, according to reports from Business Standard. The healthcare sector has demonstrated remarkable resilience, trading at new life-time highs despite the overall tepid sentiment in the market amid the US-Iran war. Sai Life Sciences led the gains with a 27.4% surge to a record ₹1,240, while Aster DM rallied 22.2% to ₹815 and Apollo Hospitals gained 16.2% at ₹8,624. As reported by Business Standard, Kranthi Bathini, equity strategist at WealthMills Securities, attributed the sector's outperformance to its immunity from external factors and domestic-driven nature.
Technical analysts Hitesh Tailor of Choice Broking and Jatin Gedia of Teji Mandi remain bullish on these healthcare stocks and expect them to scale further highs, as reported by Business Standard. For Apollo Hospitals, Jatin Gedia expects the stock to target ₹9,200-₹9,300 levels in the medium-term, implying a potential upside of around 10% from current levels. Hitesh Tailor notes that the stock has been exhibiting strong bullish momentum and continues to trade above all its key moving averages. For Aster DM Healthcare, analysts expect the stock to continue its uptrend toward ₹870-₹900 levels with up to 10.7% upside potential, while maintaining support around ₹673–₹655 levels. The stock recently delivered a decisive breakout above its previous swing high near ₹736.
Sai Life Sciences has been in an uptrend for the past eight weeks and analysts project up to 17% upside potential from current levels, according to Business Standard reports. Jatin Gedia of Teji Mandi has set medium-term targets in the ₹1,350-₹1,400 range, with the stock having recently witnessed a decisive breakout from a consolidation pattern. The analyst recommends looking for buying opportunities at the support zone around ₹1,100-₹1,080. Hitesh Tailor notes that while some consolidation or profit-booking cannot be ruled out after the recent sharp rally, the overall bias remains positive as long as key support levels hold.
According to Business Standard reports, the healthcare sector has outperformed as it is immune from external factors, with most healthcare stocks rallying following the announcement of US trade tariffs. The sector's domestic-driven nature has provided stability during uncertain global conditions. Analysts emphasize that the healthcare sector's isolation from external factors, combined with sustained domestic demand, has been a key driver of the current rally. The technical analysis suggests that these stocks continue to exhibit strong bullish momentum and healthy trend structures, with analysts maintaining positive outlooks despite potential near-term consolidation phases.
